Gao Ming-Zhu, Wang Nian-Fei, Wang Jin-You, Ma Li, Yang Yu-Cai
Department of Oncology, the Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China.
Department of Urology, the Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China.
World J Clin Cases. 2024 Oct 6;12(28):6230-6236. doi: 10.12998/wjcc.v12.i28.6230.
Sarcomatoid renal cell carcinoma (SRCC) is a rare variant of renal cell carcinoma associated with an unfavorable prognosis. The efficacy of conventional chemotherapy and targeted therapies are limited, whereas the emergence of immune checkpoint inhibitor has introduced new avenues for managing advanced SRCC.
A 77-year-old female patient was referred to our hospital following the incidental detection of a right kidney tumor without specific symptoms. The tumor was successfully resected, and subsequent pathological examination confirmed SRCC. She experienced both local recurrence and distant metastasis eight months after the initial laparoscopic resection. Following six cycles of toripalimab combined with pirarubicin chemotherapy, the patient achieved a partial response. Subsequently, the patient attained an almost-complete continuous response to toripalimab monotherapy maintenance for an additional six cycles. She has not experienced disease progression for 15 months, and her overall survival has reached 24 months thus far.
Combination therapy with programmed death 1 antibodies and cytotoxic agents may be a recommended first-line treatment approach for SRCC.
肉瘤样肾细胞癌（SRCC）是肾细胞癌的一种罕见变体，预后不良。传统化疗和靶向治疗的疗效有限，而免疫检查点抑制剂的出现为晚期SRCC的治疗开辟了新途径。
一名77岁女性患者因偶然发现右肾肿瘤且无特定症状而转诊至我院。肿瘤成功切除，随后的病理检查确诊为SRCC。初次腹腔镜切除术后八个月，她出现了局部复发和远处转移。在接受六个周期的托瑞帕利单抗联合吡柔比星化疗后，患者获得部分缓解。随后，患者接受托瑞帕利单抗单药维持治疗六个周期，获得了几乎完全的持续缓解。她已经15个月没有出现疾病进展，迄今为止总生存期已达24个月。
程序性死亡1抗体与细胞毒性药物联合治疗可能是SRCC推荐的一线治疗方法。
